Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Decreases By 11.0%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIOGet Rating) was the recipient of a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 5,500,000 shares, a decrease of 11.0% from the August 15th total of 6,180,000 shares. Based on an average trading volume of 799,900 shares, the days-to-cover ratio is currently 6.9 days. Approximately 10.2% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AGIO. The Goldman Sachs Group lowered their price target on shares of Agios Pharmaceuticals from $20.00 to $16.00 and set a “sell” rating on the stock in a report on Tuesday, May 24th. SVB Leerink increased their price target on shares of Agios Pharmaceuticals from $33.00 to $37.00 and gave the company an “outperform” rating in a report on Friday, August 5th. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $51.14.

Agios Pharmaceuticals Trading Down 9.5 %

NASDAQ AGIO opened at $30.84 on Monday. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -4.59 and a beta of 1.18. The firm’s 50 day simple moving average is $26.53 and its 200 day simple moving average is $25.07. Agios Pharmaceuticals has a 1 year low of $16.75 and a 1 year high of $50.98.

Agios Pharmaceuticals (NASDAQ:AGIOGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.78) by $0.10. The firm had revenue of $5.58 million for the quarter, compared to analyst estimates of $2.86 million. The business’s revenue was up 5482.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.36) EPS. On average, equities research analysts forecast that Agios Pharmaceuticals will post -6.89 earnings per share for the current year.

Institutional Trading of Agios Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its stake in shares of Agios Pharmaceuticals by 34.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 725,401 shares of the biopharmaceutical company’s stock valued at $23,845,000 after acquiring an additional 184,903 shares during the last quarter. State Street Corp grew its holdings in Agios Pharmaceuticals by 25.1% in the fourth quarter. State Street Corp now owns 2,992,882 shares of the biopharmaceutical company’s stock worth $98,376,000 after purchasing an additional 599,992 shares during the period. Squarepoint Ops LLC acquired a new stake in Agios Pharmaceuticals in the fourth quarter worth $1,401,000. WINTON GROUP Ltd boosted its holdings in Agios Pharmaceuticals by 18.0% during the first quarter. WINTON GROUP Ltd now owns 22,138 shares of the biopharmaceutical company’s stock worth $644,000 after purchasing an additional 3,382 shares during the last quarter. Finally, Rock Springs Capital Management LP raised its position in Agios Pharmaceuticals by 0.7% in the first quarter. Rock Springs Capital Management LP now owns 2,665,275 shares of the biopharmaceutical company’s stock worth $77,586,000 after acquiring an additional 18,650 shares during the period.

Agios Pharmaceuticals Company Profile

(Get Rating)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.

Recommended Stories

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.